Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts

Pragya Srivastava, Benjamin E. Paluch, Junko Matsuzaki, Smitha R. James, Golda Collamat-Lai, Julia Karbach, Michael J. Nemeth, Pietro Taverna, Adam R. Karpf, Elizabeth A. Griffiths

Research output: Contribution to journalArticlepeer-review

74 Scopus citations


The mechanism of clinical action for the FDA approved hypomethylating drugs azacitidine and decitabine remains unresolved and in this context the potential immunomodulatory effect of these agents on leukemic cells is an area of active investigation. Induced expression of methylated Cancer Testis Antigen (CTA) genes has been demonstrated in leukemic cell lines following exposure to hypomethylating drugs in vitro. SGI-110 is a novel hypomethylating dinucleotide with prolonged in vivo exposure and clinical activity in patients with MDS and AML. We demonstrate that this agent, like decitabine, produces robust re-expression of the CTAs NY-ESO-1 and MAGE-A, both in vitro and in leukemia-bearing AML xenografts. Upregulation of these genes in vitro was sufficient to induce cytotoxicity by HLA-compatible CD8+ T-cells specific for NY-ESO-1, a well-recognized and immunogenic CTA. Additionally, exposure to SGI-110 enhances MHC class I and co-stimulatory molecule expression, potentially contributing to recognition of CTAs. SGI-110, like the parent compound decitabine, induces expression of CTAs and might modulate immune recognition of myeloid malignancy.

Original languageEnglish (US)
Pages (from-to)1332-1341
Number of pages10
JournalLeukemia Research
Issue number11
StatePublished - Nov 1 2014


  • Acute myeloid leukemia
  • Cancer germline genes
  • Cancer testis antigens
  • DNA methylation
  • DNA methyltransferase inhibitors
  • Epigenetics
  • Immune modulation
  • SGI-110

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts'. Together they form a unique fingerprint.

Cite this